Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
lunes, noviembre 16
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
AbbVie Inc
ABBV
NYSE
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$295.03
0.58
0.2%
al cierre: Nov 13, 4:00 PM EST
$294.88
-0.15
-0.05%
After hour: Nov 13, 7:57 PM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Dividendos
Comparar
Informe de acciones
AbbVie Financials
AbbVie (ABBV) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
AbbVie Analysts Raise Price Target After Q3 Print, Expect Growth To Reaccelerate
AbbVie shares fell 2% despite Q3 revenue and EPS beats; analysts raised targets, citing immunology strength and long-term growth prospects.
Priya Nigam
These Analysts Increase Their Forecasts On AbbVie After Strong Q3 Results
AbbVie beats Q3 estimates, raises 2026 revenue and earnings outlook, while analysts lift price targets to as high as $338.
Avi Kapoor
AbbVie Raises 2026 Outlook, Boosts Dividend
AbbVie hits a new 52-week high after beating Q3 2026 earnings estimates, raising its full-year guidance, and boosting its dividend.
Vandana Singh
PRO
Conference call: AbbVie Raises FY2026 Sales Guidance from $67.600B to $67.800B vs $67.585B Est
AbbVie (NYSE:ABBV) raises FY2026 sales outlook from $67.600 billion to $67.800 billion vs $67.585 billion estimate.
Benzinga Newsdesk
PRO
Conference call: AbbVie Sees Q4 Adj EPS $3.83-$3.87 vs $3.89 Est; Sees Sales $18.400B vs $18.300B Est
AbbVie (NYSE:ABBV) is looking for Q4 Adj EPS of $3.83-$3.87 vs $3.89 analyst estimate. sees sales of $18.400 billion vs $18.300 billion analyst estimate.
Benzinga Newsdesk
PRO
AbbVie Raises FY2026 Adj EPS Guidance from $13.76-$13.96 to $13.95-$13.99 vs $13.93 Est
AbbVie (NYSE:ABBV) raises FY2026 Adj EPS guidance from $13.76-$13.96 to $13.95-$13.99 vs $13.93 analyst estimate..
Benzinga Newsdesk